Lupin Inks $60-Million Biosimilar Deal With Zentiva For Certolizumab PegolL

Lupin Ltd. has signed a commercialisation deal with Czechoslovakia-based Zentiva k.s. for its biosimilar Certolizumab Pegol in select global markets, the company said in a stock exchange filing.

Under the agreement, Zentiva will pay Lupin $10 million upfront, with up to $50 million linked to regulatory milestones across various geographies. The biosimilar is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and spondylitis.

Both companies will co-invest in developing the biosimilar and share profits from the defined markets. Zentiva will handle commercialisation in Europe and the Commonwealth of Independent States, leveraging its regulatory and distribution network. Lupin will retain marketing rights for the US, Canada, Australia, Japan, Brazil, the Philippines, and India.